ジェネリック医薬品のヨーロッパ市場

【英語タイトル】Generics in Europe

MarketLineが出版した調査資料(MLINE7081004)・商品コード:MLINE7081004
・発行会社(調査会社):MarketLine
・発行日:2017年1月31日
・ページ数:32
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:ヨーロッパ
・産業分野:製薬
◆販売価格オプション(消費税別)
Single UserUSD350 ⇒換算¥39,200見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD700 ⇒換算¥78,400見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD1,050 ⇒換算¥117,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

SummaryGenerics in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Europe
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Europe
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Europe generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the Europe generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the Europe generics market by value in 2016?
- What will be the size of the Europe generics market in 2021?
- What factors are affecting the strength of competition in the Europe generics market?
- How has the market performed over the last five years?
- How large is Europe’s generics market in relation to its regional counterparts?

Key Highlights
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the ‘generic-eligible’ market, are not included.

The European generics market is expected to generate total revenues of $49.5bn in 2016, representing a compound annual growth rate (CAGR) of 5.8% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 1.2% between 2012 and 2016, to reach a total of 70.8% of total pharma volume in 2016.

The European market is dominated by markets with high generic uptake, including those in Western Europe, such as the UK and Germany, as well as those in Eastern Europe, such as Russia and Poland. However, markets such as France and Norway provide scope for the generics market to grow.

【レポートの目次】

Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Mylan Inc.
Sandoz International GmbH
Sanofi SA
Teva Pharmaceutical Industries Limited
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

Table 1: Europe generics market value: $ billion, 2012-16(e)
Table 2: Europe generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Europe generics market geography segmentation: $ billion, 2016(e)
Table 4: Europe generics market value forecast: $ billion, 2016-21
Table 5: Europe generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (€)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

Figure 1: Europe generics market value: $ billion, 2012-16(e)
Figure 2: Europe generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Europe generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Europe generics market value forecast: $ billion, 2016-21
Figure 5: Europe generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Europe, 2016
Figure 7: Drivers of buyer power in the generics market in Europe, 2016
Figure 8: Drivers of supplier power in the generics market in Europe, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Europe, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Europe, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Europe, 2016
Figure 12: Mylan Inc.: revenues and profitability
Figure 13: Mylan Inc.: assets and liabilities
Figure 14: Sanofi SA: revenues and profitability
Figure 15: Sanofi SA: assets and liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues and profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets and liabilities

★調査レポート[ジェネリック医薬品のヨーロッパ市場] (コード:MLINE7081004)販売に関する免責事項を必ずご確認ください。
★調査レポート[ジェネリック医薬品のヨーロッパ市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆